| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d92cadef62bee04776f42fee47b4bf2a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-42 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y404-01011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-88 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74 |
| filingDate |
2017-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7e303a7c5fdf2d91e869281b9fae085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7631f7f7ae5ddfcb350e4f57e844f43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db9c8bb4914418f0f9ab15e76e58216a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_901aa469aed6905b01aa1a4dabae920a |
| publicationDate |
2017-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-107115533-A |
| titleOfInvention |
Application of Genetic Engineering Bacteria VNP20009-M in the Preparation of Drugs for the Treatment of Malignant Sarcoma |
| abstract |
The invention belongs to the technical field of genetic engineering drugs, and in particular relates to a new application of genetic engineering bacteria VNP20009‑M in the preparation of drugs for the prevention and treatment of malignant sarcoma. The invention discloses that the genetically engineered bacteria VNP20009-M is used for treating malignant sarcoma on the existing basis, the genetically engineered bacteria VNP20009-M can effectively kill tumor cells and eliminate tumor lesions, and the genetically engineered bacteria are harmless to the human body. It has obvious toxic and side effects, and provides a safe and effective new way for the treatment of malignant sarcoma. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018177375-A1 |
| priorityDate |
2017-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |